Alsevalimab
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab , and shows good safety profiles[1].
Product Specifications
CAS Number
2254029-91-7
UNSPSC
12352203
Target
CD276/B7-H3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/alsevalimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Alsevalimab]
Molecular Weight
(144.74 kDa)
References & Citations
[1]Phipps M, Falchook GS. B7 Homolog 4 (B7-H4) -Directed Agents in Oncology Clinical Trials: A Review. J Immunother Precis Oncol. 2025 Apr 10;8 (2) :153-160.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
